Kemper (KMPR) closed the last trading session at $63.29, gaining 1.3% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $82.2 indicates a 29.9% upside potential.The average comprises five short-term price targets ranging from a low of $75.00 to a high of $90.00, with a standard deviation of $5.72. While the lowest estimate indicates an increase of 18.5% from the current price level, ...

Qifu Technology, Inc. (QFIN) closed the last trading session at $43.06, gaining 1.3% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $54.8 indicates a 27.3% upside potential.The mean estimate comprises four short-term price targets with a standard deviation of $4.14. While the lowest estimate of $50.00 indicates a 16.1% increase from the current price level, the most optimistic ana ...

Core Viewpoint - The article discusses the reliability of brokerage recommendations, particularly focusing on Teradyne (TER), and highlights the potential misalignment of interests between brokerage analysts and retail investors [1][5][10]. Group 1: Brokerage Recommendations for Teradyne - Teradyne has an average brokerage recommendation (ABR) of 1.93, indicating a consensus between Strong Buy and Buy, with 60% of recommendations being Strong Buy and 6.7% being Buy [2][4]. - The article suggests that relying solely on the ABR for investment decisions may not be advisable, as studies indicate that brokerage recommendations often fail to guide investors effectively [5][10]. Group 2: Limitations of Brokerage Recommendations - Brokerage analysts tend to exhibit a strong positive bias in their ratings due to vested interests, resulting in a disproportionate number of favorable ratings compared to negative ones [6][10]. - The article emphasizes that the best use of brokerage recommendations is to validate independent research rather than as a primary decision-making tool [7][10]. Group 3: Zacks Rank vs. ABR - Zacks Rank is presented as a more reliable tool for predicting stock performance, based on earnings estimate revisions, and is categorized into five groups from Strong Buy to Strong Sell [8][11]. - Unlike ABR, which may not be up-to-date, Zacks Rank reflects timely changes in earnings estimates, making it a more effective indicator for future stock prices [12]. Group 4: Current Earnings Estimates for Teradyne - The Zacks Consensus Estimate for Teradyne remains unchanged at $3.16 for the current year, suggesting stable analyst views on the company's earnings prospects [13]. - Due to the unchanged consensus estimate and other factors, Teradyne holds a Zacks Rank of 3 (Hold), indicating a cautious approach despite the Buy-equivalent ABR [14].

Shares of Rapt Therapeutics (RAPT) have gained 1.7% over the past four weeks to close the last trading session at $7.84, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $30 indicates a potential upside of 282.7%.The average comprises four short-term price targets ranging from a low of $8.00 to a high of $48.00, with a standard deviation of $21.04. While the lowest estimate indic ...

Company Overview - PACS Group, Inc. shares increased by 21.8% to close at $12.35, with trading volume significantly higher than usual, contrasting with a 6.2% loss over the past four weeks [1] - The company is undergoing an audit committee investigation, which is nearly complete, and no integrity issues have been found regarding top management [2] Financial Performance - PACS Group is expected to report quarterly earnings of $0.42 per share, reflecting a year-over-year increase of 10.5%, with revenues projected at $1.09 billion, up 16.5% from the previous year [3] - The consensus EPS estimate for the upcoming quarter has remained unchanged over the last 30 days, indicating stability in earnings expectations [4] Industry Context - PACS Group operates within the Zacks Medical Services industry, where Sotera Health Company, a peer, has seen a 3.3% decline in its stock price recently and a negative return of 11.6% over the past month [4] - Sotera Health's consensus EPS estimate has also remained unchanged, currently at $0.17, which is a decrease of 10.5% compared to the previous year [5]

The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price. Do they really matter, though?Let's take a look at what these Wall Street heavyweights have to say about RTX (RTX) before we discuss the reliability of brokerage recommendations and how to use them to your advantage.RTX currently has an average brokerage ...

Immunome, Inc. (IMNM) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting stock prices -- has triggered this rating change.The Zacks rating relies solely on a company's changing earnings picture. It tracks EPS estimates for the current and following years from the sell-side analysts covering the stock through a consensus measure -- the Zacks Consensus Estimate.Individual investors of ...

Alithya Group (ALYAF) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting stock prices -- has triggered this rating change.The Zacks rating relies solely on a company's changing earnings picture. It tracks EPS estimates for the current and following years from the sell-side analysts covering the stock through a consensus measure -- the Zacks Consensus Estimate.Since a changing earnings pictu ...

Shares of Arvinas, Inc. (ARVN) have gained 13.9% over the past four weeks to close the last trading session at $7.39, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $14.03 indicates a potential upside of 89.9%.The mean estimate comprises 17 short-term price targets with a standard deviation of $4.54. While the lowest estimate of $8 indicates an 8.3% increase from the current pr ...

Avadel (AVDL) closed the last trading session at $9.57, gaining 6.2% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $17.38 indicates an 81.6% upside potential.The mean estimate comprises eight short-term price targets with a standard deviation of $3.70. While the lowest estimate of $12 indicates a 25.4% increase from the current price level, the most optimistic analyst expects the ...